Overview

5-Way Crossover Study to Compare the Safety, Tolerability and Pharmacokinetics of New Oral Cannabinoid Formulations Administered as Single Doses, With Buccal Sativex®, in Healthy Volunteers

Status:
Completed

Trial end date:
2016-06-06

Target enrollment:

Participant gender:

Summary

The primary objective of the study was to evaluate the safety and tolerability of novel oral capsules containing THC and/or CBD, following a single administration to healthy volunteers. The secondary objective of the study was to compare the pharmacokinetic profiles of THC, THC metabolite 11-hydroxy-THC and/or CBD following a single administration of the investigational oral formulations with Sativex® Oromucosal Spray.

Phase:

Phase 1

Details

Lead Sponsor:

PhytoTech Therapeutics, Ltd.

Treatments:

Nabiximols